OTLK logo

OUTLOOK THERAPEUTICS INC

OTLKNASDAQ
🏆 #4016 by market capEarnings Dec 17 · PostUS Equity
$133.77▲ $10.70 (+8.00%)
Simulated price
🔔
Track OTLK
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 8.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$117M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
195.6%
High
💵FCF Margin
4911.8%
Strong
⚖️P/S Ratio
-100.6x
Cheap
Otter Score
72
Fair
No chart data available for OTLK.

Trading Snapshot

Day Range
$132.84 – $136.42
52-Week Range
$0.16 – $2.54
Volume
$2.81B
Avg Volume
$2.04B
Shares Outstanding
187.0M
Next Earnings
Dec 5, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$9,000
P/E Ratio
-0.3
P/S Ratio
-100.6x
EPS (TTM)
$-2.40
Dividend Yield
0.00%
Dilution (1yr)
+5.1%

Why Investors Own OTLK

  • ✓High-growth profile — revenue up +29.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 57% gross margin and 15% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

OTLK logo

OUTLOOK THERAPEUTICS INC

OTLK
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1M▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$67M▼ −6.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$52M▼ −24.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
25.5M▲ +5.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$28M▼ −$3M YoY
StockOtter · stockotter.space

About OUTLOOK THERAPEUTICS INC

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$156.63
▲ +17.1% Upside
High Target$193.38
Low Target$126.15
Based on 28 analysts

Latest News & Updates

🚀
CNBC·2h ago

OUTLOOK THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift OTLK price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

OUTLOOK THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.